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Introduction
At the two largest American cardiological congresses held 
over the past year — the American Heart Association Scien-
tific Session 2018 and the American College of Cardiology 
2019 — there was, as usual, an abundance of important 
results of the latest clinical trials presented as part of 
the late-breaking clinical trials session. The following is 
a subjective selection of the most interesting of these, 
which confirmed the effectiveness of pharmacotherapy, as 
well as several reports that undermined the effectiveness 
of some supplements in the prevention of heart disease.
Prevention
With the current level of knowledge, it is debatable whether 
unsaturated omega 3 fatty acids, including eicosapentae-
noic acid (EPA) and docosahexaenoic acid (DHA), have the 
desired effect on overall mortality as well as the incidence 
of cardiovascular incidents. New information on their 
preventive effects was supposed to be provided by two 
studies presented at the congress: REDUCE-IT (primary and 
secondary prevention) and VITAL (VITamin D and OmegA-3 
TriaL) (primary prevention).
REDUCE-IT — a new era of prevention  
of cardiovascular incidents  
with high doses of EPA ethyl ester?
REDUCE-IT was planned as a multicentre, randomised, 
double-blind, placebo-controlled clinical trial, which in-
cluded both patients with documented cardiovascular 
disease (CVD) (secondary prevention group) and patients 
with diabetes and CVD (primary prevention group) as well 
as at least one risk factor.
The study included patients whose triglyceride fraction 
(TG, triglycerides) was 134–499 mg/dL, and whose low-
-density lipoprotein (LDL) cholesterol fraction was in the 
range 41–100 mg/dL. Patients were randomly divided into 
groups receiving placebo (mineral oil) or 4 g (in two doses 
of 2 g) of EPA ethyl ester per day — an organic chemical 
compound from the group of omega 3 acids, which is 
a highly purified and stable form [1]. The primary composite 
endpoint of the study was death, myocardial infarction, non-
-fatal stroke, coronary revascularisation, or unstable angina 
(UA). The secondary composite endpoint, however, included 
cardiovascular death, non-fatal myocardial infarction, and 
stroke. Eventually, 8,179 patients were enrolled in the 
study, of whom 70.7% were patients from the secondary 
prevention group of cardiovascular incidents.
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associated with the reduction of first-time cardiovascular 
incidents, but it also significantly reduces the incidence of 
subsequent adverse events.
The primary endpoint of the study was to assess the 
overall incidence of cardiovascular incidents (first-time 
and subsequent) in the form of cardiovascular death, myo-
cardial infarction, central nervous system (CNS) stroke, 
coronary revascularisation, or hospitalisation due to UA. 
The secondary evaluated endpoint was cardiovascular 
death, myocardial infarction, or stroke within the central 
nervous system. In the study group of 8,179 patients, which 
was observed for nearly five years (median 4.9 years), 
1,606 (55.2%) had the first-time composite primary end-
point, and 1,303 (44.8%) an event within the composite 
primary endpoint. This endpoint was the next already repor-
ted cardiovascular episode in a given patient (in the case of 
762 patients it was the second episode, in 541 it was the 
third or subsequent one. The use of EPA was found to redu-
ce (relative risk [RR], 0.7; 95% CI: 0.62–0.78; p < 0.001) 
the risk of having a complex primary endpoint by 30%, as 
well as (RR = 0.72; 95% CI: 0.63–0.83; p < 0.001) the risk 
of the composite secondary endpoint by 28%. In-depth 
analyses showed that the use of EPA at a dose of 4 g/day 
in a group of 1,000 patients for five years would help avoid 
12 deaths due to cardiovascular causes, 42 heart attacks, 
14 strokes in the CNS, 76 cases of coronary revascularisa-
tion, and 16 hospitalisations because of UA [4].
EPA concentration in the serum  
phospholipid fraction and the risk  
of developing heart failure
The previously encouraging results of the cardioprotective 
effect of EPA supplementation on the occurrence of ad-
verse cardiovascular events (mainly macroangiopathic), 
described above, have contributed to a search for its 
beneficial effects in other areas. In their study, Block et 
al. [5] attempted to assess the relationship between the 
percentage of EPA in the overall plasma phospholipid 
fraction and the risk of developing heart failure (HF). They 
included 6,562 patients aged 45–82 in their prospective 
cohort observational study and measured the baseline 
EPA fraction. During the clinical follow-up (median 13 
years), 282 (4.3%) new episodes of HF were recorded: 
128 cases with reduced ejection fraction (HFrEF), 110 
cases of heart failure with preserved ejection fraction 
(HFpEF), and 54 HF with left ventricle (LV) systolic fun-
ction. As demonstrated by the authors, the percentage 
of plasma phospholipid EPA fractions linearly correlated 
with a decrease in the risk of developing HF, regardless 
of its type (HR 0.73; 95% CI: 0.60–0.91; for logarithmised 
%EPA), and this relationship was maintained after making 
adjustments according to age, gender, individual lipid 
profile fractions, and co-morbidities such as diabetes or 
arterial hypertension (AH) [5].
One year after enrollment in the study, the EPA ethyl 
ester group had a significantly greater reduction in the 
concentration of lipid profile TG fractions, the concentra-
tions of which decreased by an average of 18.3% (median 
decrease of 39 mg/dL) from baseline, while in the placebo 
group they had increased by 2.2% (median 4.5 mg/dL). In 
addition, LDL cholesterol increased in both the intervention 
group (median increase 2 mg/dL) and the control group 
(median increase 7 mg/dL), but in the placebo group, this 
increase was 6.6% higher (p < 0.001).
During the average follow-up period of 4.9 years, the 
primary endpoint occurred significantly less frequently in 
patients receiving the EPA derivative than in those receiving 
placebo [17.2% vs. 22.0%; hazard ratio (HR) 0.75; 95 per-
centile confidence interval (CI): 0.68–0.83; p < 0.001]. The 
frequency of the secondary endpoint was 11.2% compared 
to 14.8% (HR = 0.74; 95% CI: 0.65–0.83; p < 0.001). Sur-
prisingly, in the intervention group a statistically significant 
20% reduction in the risk of death from cardiovascular 
causes was observed (4.3% vs. 5.2%; HR = 0.80; 95% CI: 
0.66–0.98; p = 0.03). In terms of the safety of the treat-
ment, it should be emphasised that a significantly higher 
incidence of hospitalisation due to atrial fibrillation/atrial 
flutter (3.1% vs. 2.1%; p = 0.004) and a trend towards more 
frequent major bleeding were observed among patients 
receiving the EPA derivative. 2.7% vs. 2.1%; p = 0.06), and 
that the exact origin of this type of side effect is not known.
Among the main objections raised by the study protocol 
was the use of mineral oil (light, liquid paraffin oil) in the 
placebo group, the consistency, colour and even flavour of 
which were designed to imitate the EPA derivative used in 
the intervention group. The main doubts were raised by the 
fact that there was an increase in LDL cholesterol and high-
-sensitivity C-reactive protein (hs-CRP) relative to baseline 
in the placebo group. This could suggest an adverse effect 
of the substance used as the placebo, which by definition 
should have no effect on the patients. Nevertheless, the 
subanalysis presented by the researchers (excluding 
patients in whom these changes were observed) did not 
affect the observed effect of a significant reduction in the 
incidence of the complex endpoint.
The purpose of this study was not to explain biologically 
beneficial mechanisms of the EPA derivative. It can be assu-
med that this effect may be a derivative of an action leading 
to a decrease in TG value, anticoagulant, antiplatelet and 
membrane stabilising effects, stabilising atherosclerotic 
plaques, and reducing inflammation — this pleiotropism has 
been shown in numerous previous studies [2, 3].
REDUCE-IT Total Events
In their study, which is a continuation of the presented 
analyses on the effectiveness of EPA in the prevention of 
cardiovascular diseases, Bhatt et al. [4] also proved that its 
use according to the protocol presented earlier is not only 
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VITAL — assessment of the effectiveness  
of omega 3 and vitamin D3 supplementation 
in the primary prevention of cardiovascular 
incidents and cancers
Nearly half of adults in Western countries take dietary 
supplements. Over the past decade, the number of people 
taking fish oil-based preparations has increased tenfold, 
and the number of people supplementing with vitamin D3 
has increased fourfold. All this is happening at a time when 
we do not have research results presenting clear evidence 
of the health benefits of this type of long-term supplemen-
tation. New information in this regard was to be provided 
by the VITAL study, which was designed as a multicentre, 
randomised, double-blind, placebo-controlled observatio-
nal study aimed to assess the impact of supplementation 
with omega 3 and vitamin D3 in the primary prevention 
concerning the incidence of cardiovascular events and 
cancers in the general population. The study included men 
aged 50-plus as well as women aged 55-plus. The primary 
composite endpoints were the occurrence of a major ad-
verse cardiac event (MACE) in the form of a heart attack, 
stroke or cardiovascular death, and any invasive cancer. 
The secondary endpoints were all individual components 
of the primary endpoint separately, and the primary com-
posite endpoint extended by coronary revascularisation 
(percutaneous coronary intervention [PCI]) or coronary 
artery bypass grafting [CABG], tumour specific to individual 
systems, and death caused by cancer. The safety of the 
treatment was also assessed.
VITAL — omega 3 and cardiovascular  
incidents and cancers
A total of 25,791 patients with an average age of 67.1 
were included in the analysis of omega 3 supplementa-
tion. The intervention consisted of supplementation with 
a 1 g/day omega 3 preparation (1 g of fish oil containing 
840 mg of fatty acids, including 460 mg of EPA and 380 
mg of DHA). The median follow-up covered more than 
five years. There were no significant differences in the 
incidence of MACE incidents between the groups in the 
follow-up (MACE occurred in 386/12,933, i.e. 2.98% of 
the patients in the omega 3 group and 419/12,938, i.e. 
3.23% of the patients in the group receiving placebo — HR 
0.92; 95% CI: 0.80–10.6; p = 0.24). A newly diagnosed 
invasive tumour during the clinical follow-up was reported 
in a similar percentage of patients in both groups (820 pa-
tients in the omega 3 group and 797 in the placebo group; 
HR = 1.3; 95% CI: 0.93–1.13; p = 0.56). In the analysis of 
key secondary endpoints, no significant differences were 
observed in the incidence of the composite endpoint ex-
tended by the need for revascularisation (HR = 0.93; 95% 
CI: 0.82–1.04), stroke (HR = 1.04; 95% CI: 0.83–1.31), 
death because of cardiovascular causes (HR = 0.96; 95% 
CI: 0.76–1.21), or death caused by cancer (HR = 0.97; 95% 
CI: 0.79–1.20). However, there was a low risk of a heart 
attack in the group receiving omega 3 (HR = 0.72; 95% 
CI: 0.59–0.90), which partly seems to be consistent with 
the results of the REDUCE-IT study discussed earlier. There 
were also no significant differences between the omega 3 
and the placebo groups in the risk of death from any cause 
(3.81% vs. 3.75%; HR = 1.02; 95% CI: 0.90–1.15; a total 
of 978 deaths during follow-up). Also, a subgroup analysis 
showed that potentially the greatest benefit of omega 3 
supplementation in terms of MACE prevention could be for 
people with a low fish oil intake, defined as the average 
weekly consumption of less than 1.5 fish-based meals. 
In this group of patients, omega 3 supplementation was 
associated with a 19% reduction in the risk of adverse 
cardiovascular events (HR = 0.81; 95% CI: 0.67–0.98).
In terms of safety analysis, no effects of omega 3 sup-
plementation on the incidence of significant bleeding, 
gastrointestinal symptoms, or other serious adverse effects 
were observed [6]. Further analysis regarding the effects of 
omega 3 on diabetes, atrial fibrillation, cognitive function, 
autoimmune disorders, and other conditions that may 
significantly impact the final benefit and risk assessment 
of omega 3 supplementation is ongoing [6].
VITAL — vitamin D3  
and cardiovascular incidents/cancer
When analysing the VITAL study for vitamin D3 supplemen-
tation, 25,871 patients were randomised. They were divi-
ded into a placebo group (N = 12,944) and an intervention 
group with vitamin D3 (cholecalciferol) supplementation 
at a dose of 2,000 units of measure/day (N = 12,927). 
The average age of the studied population was 67.1 years, 
nearly half of the patients had AH (49.8%), and 13.7% had 
diabetes. The average baseline vitamin D3 concentration 
was 30.8 ± 10.0 ng/mL. In 12.7% of the patients this value 
was lower than 20 ng/mL (severe deficiency), and in the 
case of 32.2% of the patients vitamin D3 concentration 
was in the range of 20–30 ng/mL (deficiency). In the 
intervention group, the average vitamin D3 concentra-
tion increased by 40% after a year of observation (from 
an average of 29.9 ng/mL to one of 41.8 ng/mL), while 
in the control group it remained unchanged. During the 
follow-up period, whose median was more than five years, 
there were no statistically significant differences between 
the groups in the frequency of MACE (taking placebo — 
3.16% vs. taking vitamin D3 — 3.06%; HR 0.97%, 95% CI: 
0.85–1.12) or cancer (taking placebo — 6.36% vs. taking 
vitamin D3 — 6.13%; HR 0.96, 95% CI: 0.88–1.06). In 
terms of secondary endpoints, no significant differences 
were observed when it came to the risk of death from 
any cancer (HR 0.83; 95% CI: 0.67–1,02). There was 
no effect of vitamin D3 supplementation on the risk of 
any of the following cancers: breast (HR 1.02; 95% CI: 
0.79–1.31), prostate (HR 0.88; 95% CI: 0.72–1.07), or 
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large intestine and rectum (HR 1.09; 95% CI: 0.73–1.62). 
In addition, an in-depth analysis did not show an effect 
of vitamin D3 supplementation on the incidence of MACE 
associated with coronary revascularisation (HR 0.96; 
95% CI: 0.86–1.08), myocardial infarction (HR 0.96; 
95% CI: 0.78–1.19), stroke in the CNS (HR 0.95; 95% 
CI: 0.76–1.20), death from cardiovascular causes (HR 
1.11; 95% CI: 0.88–1.40), or death from any cause (HR 
0.99; 95% CI: 0.87–1.12). Also, taking into consideration 
the baseline vitamin D3 levels, the subgroup analysis 
also showed no benefit in vitamin D3 supplementation 
in terms of reducing risk of occurrence cardiovascular 
incidents and cancers in patients with severe vitamin 
D3 deficiency. Nevertheless, the results of this analysis 
should be interpreted with caution, because due to the 
fact that more than 20% (5,106/25,304) of the patients 
included in the study were black, the study is more repre-
sentative for the USA (where recruitment was carried out) 
than for example for the Caucasian population. Different 
skin pigmentation in the case of dark-skinned patients, 
and thus different production of endogenous vitamin D3, 
was not analysed in detail over time, so its effect on the 
results cannot be excluded.
Heart failure
DECLARE-TIMI 58
Patients with type 2 diabetes are at a high risk of developing 
cardiovascular disease and HF. Dapagliflozin is a compo-
und belonging to a new group of drugs with a so-called 
hypoglycaemic effect. They act as selective inhibitors of 
the sodium glucose co-transporter 2 (SGLT2) responsible 
for the reuptake of almost 80% of glucose from primary 
urine. Their mechanism of action consisting in limiting renal 
glucose reabsorption, leading to glycosuria, is associated 
with a decrease in glycaemia, blood pressure and body 
weight, while at the same time, thanks to its diuretic effect, 
they reduce the frequency of rehospitalisations associated 
with HF exacerbation.
The goal of the DECLARE-TIMI 58 (Dapagliflozin Effect 
on CardiovascuLAR Events) study was to evaluate the ef-
fect of dapagliflozin on the incidence of major adverse car-
diovascular events (MACE) defined as death, myocardial 
infarction, or ischaemic stroke, as well as cardiovascular 
mortality or rehospitalisation due to HF in patients with 
diabetes and concomitant atherosclerosis of the cardiova-
scular system [7]. The study was designed as to be rando-
mised, multicentre, double-blind, and placebo-controlled. 
The study included patients with type 2 diabetes and 
preserved kidney function (glomerular filtration rate [GFR] 
> 60 mL/min) and previously diagnosed atherosclerotic 
cardiovascular disease (coronary heart disease, athero-
sclerotic cerebrovascular disease, peripheral vascular 
disease) or burdened with concomitant risk factors for 
cardiovascular disease (age ≥ 55 years old for men or 
≥ 60 years old for women and a co-existence ≥ 1 of the fol-
lowing risk factors: AH, dyslipidemia, smoking). The study 
involved 882 centres from 33 countries recruiting a group 
of 17,160 patients (8,582 patients received dapagliflozin 
10 mg/day and 8,578 patients placebo), with a mean 
age of around 64 years, mainly men (63%). At the time 
of enrollment, 10% of the patients had been previously 
diagnosed with HF. The mean glycosylated haemoglobin 
(HbA1c) value was 8.3 ± 1.2%, and an average 11 (range 
6–16) years had passed since the diagnosis of diabetes. 
Patients underwent clinical follow-up for an average of 
4.2 (3.9–4.4) years.
In the dapagliflozin group, a significantly lower inciden-
ce of death or rehospitalisation due to HF exacerbation was 
observed (4.9% vs. 5.8%; HR 0.83; 95% CI: 0.73–0.96; 
p = 0.005), and these differences were mainly caused 
by a lower frequency of rehospitalisation due to HF in 
the dapagliflozin group (HR 0.73; 95% CI: 0.61–0.88). 
There were no differences between the groups in terms 
of cardiovascular mortality (HR 0.98; 95% CI: 0.82–1.17), 
nor death due to any other causes (HR 0.93; 95% CI: 
0.82–1.04). In addition, dapagliflozin was not associated 
with a lower incidence of MACE than in the placebo group 
(8.8% vs. 9.4%; HR 0.93; 95% CI: 0.84–1.03; p = 0.17), 
and these differences did not depend on whether the pa-
tients had previously been diagnosed with cardiovascular 
disease or only displayed the risk factors. In addition, in 
the dapagliflozin group, there was a significantly greater 
reduction in HbA1c (on average 0.42%), SBP (on average 
2.7 mm Hg) and body weight (on average 1.8 kg) compared 
to placebo. In terms of treatment safety, a higher risk of 
significant genital infections leading to discontinuation of 
treatment directly associated with glycosuria was observed 
among patients receiving dapagliflozin (0.9% vs. 0.1%; 
HR 8.36, 95% CI: 4.19–16.68; p < 0.001). In their sum-
mary, the authors emphasised that the use of SGLT2 in-
hibitors causes a much more pronounced effect on the 
prevention of episodes of chronic HF exacerbations and its 
new cases than in the case of the prevention of cardiova-
scular events themselves, which stem from atherosclerotic 
processes. Research is underway to clearly assess this 
effect of dapagliflozin in a specific patient population with 
documented HF.
EMPA-Heart Cardiolink-6
Another study evaluating the effects of a different SGLT2 
inhibitor — empagliflozin in a patient population with type 2 
diabetes and concomitant HF — was the EMPA-Heart 
Cardiolink-6 study. This study demonstrated the efficacy 
of empagliflozin in reducing cardiovascular mortality in 
patients with type 2 diabetes, but the exact mechanism 
of this effect remains unclear, and in particular, the qu-
estion of whether its use can directly affect myocardial 
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remodelling remains unanswered. The EMPA-Heart study 
was a continuation of the clinical follow-up of another study 
— EMPA-REG OUTCOME, published in 2015, which included 
7,020 patients with type 2 diabetes who were at high car-
diovascular risk. This showed that the use of empagliflozin 
is associated with a significantly lower risk of death due to 
cardiovascular causes (38% reduction), lower incidence of 
HF hospitalisation (reduction by 35%), and death from any 
other cause (reduction by 32%).
Researchers involved in the EMPA-HEART study ran-
domised 97 patients with type 2 diabetes and a history 
of confirmed ischaemic heart disease (previous revascu-
larisation or previous myocardial infarction) for treatment 
with empagliflozin 10 mg/day (N = 49) or placebo (N = 48). 
The patients’ hearts were evaluated functionally and stru-
cturally by means of magnetic resonance imaging after 
six months of this treatment. The study excluded patients 
with severe left ventricular (LV) systolic dysfunction (eje-
ction fraction [EF] < 30%), decompensated HF (New York 
Heart Association Class IV), and poorly controlled diabetes 
(HbA1c > 10%). The primary endpoint was LV muscle mass 
assessment in month 6, and secondary LV parameters such 
as end-systolic volume, end-diastolic volume, EF value, 
and biomarker change over time (N-terminal fragment of 
the N-terminal pro-B-type natriuretic peptide [NT-proBNP], 
troponin I, sST2 proteins [soluble suppression of tumouri-
genicity]). The average age of patients enrolled in the study 
was about 63 years, and most were men (93%) with conco-
mitant AH (91%), and the average time since the diagnosis 
of diabetes was about 11 years. In the empagliflozin group, 
a significant reduction in systolic blood pressure (SBP) 
(an average decrease of 6.7; 95% CI: 2.3–11.2 mm Hg; 
p = 0.003) and no significant change in diastolic blood 
pressure (SBP) were noted (p = 0.22), while no differen-
ce was seen in the placebo group. In addition, a greater 
increase in haematocrit (2.4% vs. 0.4%; p = 0.006) was 
also seen in the empagliflozin group. Most interestingly, 
in the intervention group there was a significant decrease 
in left ventricular mass indexed (LVMI) [on average by 
3.35 (95% CI: 0.81–3.35) g/m2; p = 0.01], regardless of 
the type of indexation adopted (i.e. to body surface or to 
height). An in-depth analysis showed much more limited 
LV remodelling (LVMI reduction) in patients with a higher 
LVMI at the beginning of the study (> 60g/m2). There were 
no significant changes over time in terms of NT-proBNP, 
troponin, or sST2 protein levels, which was probably the 
result of their low initial values. Importantly, the inciden-
ce of adverse events during six months of follow-up was 
comparable in both groups. The study provided significant 
“translational” results indicating a direct cardiac effect of 
empagliflozin on LV weight reduction — a parameter for 
which a close relationship with prognosis had previously 
been demonstrated. The authors also suggested that the 
effect on cardiac remodelling may be the result of a class 
of flosins showing a very similar effect on prognosis in re-
ducing the frequency of cardiovascular incidents observed 
in previous studies. Based on this, it can be assumed that 
SGLT2 inhibitors may have a positive effect on the preven-
tion of adverse heart remodelling [8].
PIONEER-HF
In a short follow-up, the exacerbation of chronic HF is asso-
ciated with a high risk of unplanned rehospitalisation and 
mortality associated with hospitalisation. The basis of the 
modern treatment of acute HF is stasis reduction [diuretics 
intravenous (i.v.)] and haemodynamic support (vasodilating 
and inotropic positive drugs), which has remained virtually 
unchanged for several decades.
Positive effects of the use of a new group of drugs — 
angiotensin II receptor antagonists and neprilysin inhibitors 
(ARNI) — sacubitril/valsartan, improving survival and redu-
cing the risk of rehospitalisation due to HF exacerbation, 
were confirmed in a patient population with chronic HFrEF 
in the PARADIGM-H study. On the other hand, the role 
of ARNI in the acute decompensated HF phase remains 
unknown, and information about the potential benefits of 
early initiation of treatment with sacubitril/valsartan in 
this group of patients was supposed to be provided by the 
PIONEER-HF study [9].
This study was designed as a multicentre, double-blind, 
control group to which patients with acute decompensa-
tion of chronic HFrEF were recruited in 129 centres in the 
USA. After initial haemodynamic stabilisation, the patients 
were randomised to the intervention group (target dose of 
97 mg sacubitril and 103 mg valsartan 2 ×/day) or to the 
control group receiving enalapril (target dose of 10 mg 
2 ×/day). The primary endpoint of treatment efficacy was to 
evaluate the change in NT-proBNP concentration in weeks 
4 and 8 from baseline. In terms of safety, the incidence 
of worsening renal function, hyperkalemia, symptomatic 
hypotension, and angioedema was assessed.
Eventually, 881 patients were enrolled in the study 
(440 patients were enrolled in the sacubitril/valsartan 
group and 441 patients in the enalapril group) with an 
average age of 61 ± 14 years, mainly male (72.1%). Of the 
patients previously diagnosed with HF (65.4%), the majority 
(59.5%) were hospitalised because of HF exacerbation in 
the last year. At the time of admission, 52.1% of the pa-
tients were not receiving angiotensin-converting enzyme 
(ACE) inhibitor or sartan. Median NT-proBNP concentration 
upon admission was 4,812 (3,050–8,745) pg/mL. The 
overwhelming majority of the patients received furosemide 
i.v. during hospitalisation (93%), and 7.7% of the patients 
were administered inotropic drugs. The median time of 
hospitalisation associated with HF exacerbation was 
5.2 (4.09–7.24) days.
During clinical follow-up, a significantly higher reduction 
in NT-proBNP concentration was obtained over time — the 
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mean reduction at weeks 4 and 8 in the sacubitril/valsartan 
group was 46.7% compared to 25.3% in the enalapril group 
(p < 0.001), and significant differences in the reduction of 
NT-proBNP concentration in favour of the intervention group 
were already recorded a week from the time of inclusion 
in the study. Interestingly, the change in NT-proBNP con-
centration was also accompanied by a significantly greater 
reduction of average troponin T levels determined by the 
high-sensitivity method (hs-TnT) (reduction in the group 
receiving sacubitril/valsartan vs. the group receiving ena-
lapril: 36.6% vs. 25.2%; p < 0.05). In addition, in additional 
subanalyses, early inclusion of sacubitril/valsartan in the 
intervention group was associated with a 44% lower risk 
of rehospitalisation within eight weeks of study enrollment 
(HR 0.56; 95% CI: 0.37–0.84). In terms of safety, there 
were no significant differences in the incidence of renal 
impairment, hyperkalaemia, symptomatic hypotension, or 
angioedema between the two groups.
The PIONEER-HF study was the first to confirm the 
safety and efficacy of early initiation of ARNI treatment 
in a patient population with decompensated HF, newly 
diagnosed acute HF, as well as patients who had not yet 
taken ACE inhibitors/sartans, or their doses were not 
optimal. Importantly, the beneficial effect of sacubitril/ 
/valsartan on the reduction of NT-proBNP, which is a bio-
marker of neurohormonal activation and haemodynamic 
stress, and also a prognostic marker of poor prognosis, 
was accompanied by a significant decrease in hs-TnT 
concentration — another biomarker reflecting myocardial 
damage, and one directly associated with a worse long-
-term prognosis in patients with HF. However, in order to 
be able to clearly assess the impact of the strategy of early 
initiation of ARNI treatment on the occurrence of hard 
endpoints (i.e. death, adverse cardiovascular events) in 
this patient population, we need to wait for the results of 
further clinical follow-ups.
INFINITY — difficulties in choosing  
optimal therapeutic goals in the case  
of hypertension
In the INFINITY study, researchers set out to assess the 
impact of intensive (compared to standard) ambulatory 
hypotension on improving physical fitness and cognitive 
function in elderly patients (≥ 75 years of age) with poorly 
controlled AH. The study included patients with SBP with 
measurements in the 150–170 mm Hg range treated with 
at least one antihypertensive drug, and patients with SBP 
over 170 mm Hg not treated or receiving a maximum of one 
antihypertensive drug, as well as patients with mean daily 
SBP greater than or equal to 140 mm Hg. Each patient was 
evaluated initially and after the follow-up in terms of areas 
with pathological enhancement of brain white matter and 
walking speed. During the follow-up, the primary endpoints 
were changes in both the parameters mentioned above. 
Eventually, 199 patients with an average age of 80 years 
were enrolled in the study and subjected to three years 
of follow-up. 99 patients were included in the intensive 
treatment group (target ≤ 130 mm Hg, achieved average 
daily SBP 131 mm Hg), and 100 patients were recruited to 
the standard treatment group (SBP target ≤ 145 mm Hg, 
reached 146 mm Hg). During the follow-up period, it was 
shown that the intensive reduction of SBP significantly 
reduced the progression of subcortical lesions (indirect 
exponent of vascular brain damage — percentile change in 
the intervention group in the area of white matter enhance-
ment: 0.29% vs. 0.48%, p = 0.03). In contrast, intensive AH 
pharmacotherapy did not translate in any way to a change 
in physical fitness — there were no significant differences in 
walking speed over time between the groups (p = 0.91), nor 
did it change cognitive functions (no significant changes 
were observed in time, as indicated by the Symbol Digit 
Modality, between the groups (p = 0.29).
These results reflect the difficulties in setting a uniform 
goal of AH treatment in the older population while excluding 
the impact on the rate of brain tissue damage [10].
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